GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Lorenzo Bianchi joins Vistage’s Malta and UAE teams as Chief Growth Officer
As Vistage grows from strength to strength both locally and internationally, this newly created role focuses on growth strategies.
Mediterrania Capital Partners CEO participates in global impact investing conferences in Tokyo
Albert Alsina was a guest speaker at the Japanese Association of Impact Investment event and was also present at PRI ...
Shawn Muscat appointed General Manager at Labranda Riviera Hotel & Spa
He has more than 20 years of experience working in the hospitality industry.
Premier Capital plc CEO Victor Tedesco to take on dual role as Chief Development Officer
The company announced that his new position comes as it continues to give priority to developing its 'footprint'.
